Pulmagen Therapeutics

Pulmagen Therapeutics

Respiratory drug development

Pulmagen develops novel and proprietary drugs for chronic respiratory diseases including COPD and asthma. These therapies aim to deliver both improved bronchodilator symptomatic relief and treat the underlying inflammatory disease process.


Pulmagen intends to progress its programs through Phase II proof-of-concept clinical trials and identify strategic partners for later stage clinical development.


The company has partnered respiratory drug development programs with AstraZeneca, Chiesi, Dr. Reddy's and Teijin.

Contact Name
Dr. Christopher Ashton

Company Position
Chief Executive Officer

Contact Address
The Coach House
Grenville Court
Britwell Road
Burnham
Slough
SL1 8DF
UK